Mylan Announces Supply Agreement with Ortho-McNeil on Oxybutynin

PITTSBURGH, Dec. 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced today that its subsidiary, Mylan Pharmaceuticals Inc., has entered into two agreements with Ortho-McNeil Pharmaceutical, Inc. and Alza Corporation relating to oxybutynin chloride extended release tablets, a generic version of DITROPAN XL® oxybutynin chloride extended release tablets.

Mylan has received tentative approval and is currently awaiting final approval from the United States Food and Drug Administration (FDA) for its 5 and 10 mg strengths of Oxybutynin. The exclusive supply agreement on all strengths of oxybutynin will be triggered upon a final appellate court decision in the current patent litigation between the parties the terms of which differ depending upon the final outcome. Ortho-McNeil has also agreed to supply Mylan with a generic version of DITROPAN XL® sooner than a final appellate court decision if another generic version enters the market. Mylan will be granted a non-exclusive, royalty bearing license to make and sell its ANDA products, the terms of which differ depending upon the final outcome of the pending patent litigation. The terms of the agreements are confidential and subject to a number of conditions, including review by the Federal Trade Commission (FTC).

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

This press release includes statements that may constitute "forward- looking statements," including with regard to the supply agreement and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent in contracts, including the breach or unenforceability of any key provision; the impact and effects of legal, FTC, FDA or other regulatory proceedings, actions or changes; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.
12/20/2005
CONTACT: Patrick Fitzgerald, or Kris King, both of Mylan Laboratories
Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)